COMPANY

TransCode Therapeutics

Keywords: oncology cancer metastatic cancer colon cancer TTX-MC138 TTX-MC138-NODAGA-Cu64

Location: Boston, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Jun 19, 2025 Grant Government grant — SBIR: $988,765 (annual award, as published), announced Jun 19, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Nov 27, 2024 Raise Private placement: $8M (total, as published), announced Nov 27, 2024. Source: company release on GlobeNewswire. source ↗
Sep 5, 2024 Trial start Phase 1/Phase 2: Study of TTX-MC138 in Subjects With Advanced Solid Tumors source ↗
Apr 4, 2023 Trial start Early phase 1: A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors source ↗

Raised: $8.0M. Last 2 years.

Nov 27, 2024 Private placement: $8M (total, as published), announced Nov 27, 2024. Source: company release on GlobeNewswire. source ↗
Jun 19, 2025 Government grant — SBIR: $988,765 (annual award, as published), announced Jun 19, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06260774	Study of TTX-MC138 in Subjects With Advanced Solid Tumors	Phase 1/Phase 2	Active, not recruiting	Sep 5, 2024	Sep 30, 2025 (actual)
NCT05908773	A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors	Early phase 1	Completed	Apr 4, 2023	Aug 23, 2023 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

2024-12-12 Raise Private raise (SEC Form D): $8.0M sold; issuer “Transcode Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗